OAM 71262
Latest Information Update: 18 Nov 2003
At a glance
- Originator Nonindustrial source
- Class Anticoagulants; Antihyperlipidaemics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Thrombosis
Most Recent Events
- 18 Nov 2003 Discontinued - Preclinical for Atherosclerosis in Sweden (unspecified route)
- 18 Nov 2003 Discontinued for Thrombosis in Japan (unspecified route)
- 20 Jul 1998 No-Development-Reported for Atherosclerosis in Sweden (Unknown route)